Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report) was down 6.9% during mid-day trading on Monday . The company traded as low as $11.89 and last traded at $11.92. Approximately 1,370,275 shares traded hands during mid-day trading, an increase of 305% from the average daily volume of 337,931 shares. The stock had previously closed at $12.80.
Silverback Therapeutics Stock Down 6.9 %
The company has a market capitalization of $429.81 million, a price-to-earnings ratio of -4.93 and a beta of 0.60. The stock has a 50 day simple moving average of $12.32 and a 200 day simple moving average of $13.07.
Silverback Therapeutics Company Profile
Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.
Featured Stories
- Five stocks we like better than Silverback Therapeutics
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Merck: 4 No-Brainer Reasons to Buy This Dip
- Find and Profitably Trade Stocks at 52-Week Lows
- Ackman Announces Major Stake in Uber: Should You Follow His Lead?
- What Are the FAANG Stocks and Are They Good Investments?
- Wells Fargo Upgraded These 3 Stocks—Here’s Why They Stand Out
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
